Twenty years on, measuring the impact of human stem cells
- Details
- Category: Research
In November 1998, the world was introduced to human embryonic stem cells, the blank slate cells that arise at the earliest stages of development and that go on to become any of the scores of cell types that make up a human. In a succinct paper published in the journal Science and heralded around the world, University of Wisconsin-Madison developmental biologist James Thomson described the first successful derivation and culturing of the master cells of life.
Breakthrough neurotechnology for treating paralysis
- Details
- Category: Research
Three paraplegics who sustained cervical spinal cord injuries many years ago are now able to walk with the aid of crutches or a walker thanks to new rehabilitation protocols that combine targeted electrical stimulation of the lumbar spinal cord and weight-assisted therapy. This latest study, called STIMO (STImulation Movement Overground), establishes a new therapeutic framework to improve recovery from spinal cord injury.
New epigenetic drug strategy to treat cancer
- Details
- Category: Research
Researchers have discovered that inhibiting CDK9, a DNA transcription regulator, reactivates genes that have been epigenetically silenced by cancer. Reactivation leads to restored tumor suppressor gene expression and enhanced anti-cancer immunity. It is the first time this particular kinase has been linked to gene silencing in mammals.
Largest census of cancer genes to help understand drug targets
- Details
- Category: Research
Researchers at the Wellcome Sanger Institute have created the first comprehensive summary of all genes known to be involved in human cancer, the "Cancer Gene Census". Describing all genes strongly implicated in causing cancer, the Census also describes how they function across all forms of this disease. Reported in Nature Reviews Cancer, the resource catalogues over 700 genes, to help scientists understand the causes of cancers, find drug targets and design treatments.
Immunotherapy may become new first line treatment in some metastatic colorectal cancers
- Details
- Category: Research
Immunotherapy with nivolumab and low-dose ipilimumab could become a new first line treatment in patients with some metastatic colorectal cancers following late-breaking results from the CheckMate-142 trial reported at the ESMO 2018 Congress in Munich. (1) The drug combination shrank tumours and had beneficial effects on survival in patients with microsatellite instabiliy (MSI)-high metastatic colorectal cancer.
Eating leafy greens could help prevent macular degeneration
- Details
- Category: Research
A new study has shown that eating vegetable nitrates, found mainly in green leafy vegetables and beetroot, could help reduce your risk of developing early-stage age-related macular degeneration (AMD). Researchers at the Westmead Institute for Medical Research interviewed more than 2,000 Australian adults aged over 49 and followed them over a 15-year period.
Targeted drugs for advanced cancer move from specialist units to community setting
- Details
- Category: Research
Nearly 1 in 4 patients with advanced cancer, treated at Comprehensive Cancer Care Network (NCCN) centres in the US, are receiving innovative drugs matched to DNA mutations in their tumours. This achievement, to be reported at the ESMO 2018 Congress in Munich,(1) shows that cutting-edge precision medicine is spreading from highly specialist cancer units to other healthcare facilities so more patients can benefit, wherever they are treated.
More Pharma News ...
- Diets rich in fish oil could slow the spread and growth of breast cancer cells
- Cancer stem cells use normal genes in abnormal ways
- Organs-on-chip technology reveals new drug candidates for Lou Gehrig's disease
- Seed oils are best for LDL cholesterol
- Could treating psoriasis in the future be as easy as going online?
- Evidence mounts linking aspirin to lower risk of ovarian cancer
- Health-related quality of life overlooked in cancer drug studies